Geron Corporation (GERN)

NASDAQ: GERN · Real-Time Price · USD
1.400
-0.070 (-4.76%)
At close: Sep 3, 2025, 4:00 PM
1.410
+0.010 (0.71%)
After-hours: Sep 3, 2025, 4:45 PM EDT
-4.76%
Market Cap893.22M
Revenue (ttm)164.45M
Net Income (ttm)-88.01M
Shares Out 638.02M
EPS (ttm)-0.13
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,027,481
Open1.460
Previous Close1.470
Day's Range1.380 - 1.480
52-Week Range1.090 - 4.825
Beta0.63
AnalystsBuy
Price Target3.71 (+165.0%)
Earnings DateAug 6, 2025

About GERN

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 1996
Employees 229
Stock Exchange NASDAQ
Ticker Symbol GERN
Full Company Profile

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Financial Statements

Analyst Summary

According to 8 analysts, the average rating for GERN stock is "Buy." The 12-month stock price target is $3.71, which is an increase of 165.00% from the latest price.

Price Target
$3.71
(165.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that management is scheduled to participate in a fireside chat on ...

7 days ago - Business Wire

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 522,000 ...

16 days ago - Business Wire

Geron Corporation Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

19 days ago - GlobeNewsWire

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to...

26 days ago - Business Wire

Geron: I Think We've Seen This Movie Before

Geron's Q2'25 sales of Rytelo (imetelstat) show clear growth, with net product revenue rising to $49M and underlying demand up 17%. Recent performance dispels fears that Rytelo's market share has alre...

26 days ago - Seeking Alpha

Geron Corporation (GERN) Q2 2025 Earnings Call Transcript

Geron Corporation (NASDAQ:GERN) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants & - Corporate Participant David Borah - Corporate Participant Dawn Carter Bir - Interim...

4 weeks ago - Seeking Alpha

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan...

4 weeks ago - Business Wire

Geron Appoints Harout Semerjian as President and Chief Executive Officer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the ...

4 weeks ago - Business Wire

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and busi...

5 weeks ago - Business Wire

Conservative Vision Of A Positive Future For Geron

This is a follow-up coverage of the Geron Corp., a small biotech company that markets first-in-class drug Imetelstat for the treatment of myelodysplastic syndrome (MDS). The first three full-quarter s...

3 months ago - Seeking Alpha

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GERN--Geron announces presentations on RYTELO® (imetelstat) at 2025 ASCO Annual Meeting and EHA 2025 Congress.

3 months ago - Business Wire

Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade)

Geron's RYTELO faces limited revenue potential in a crowded MDS market, with predominantly 3L+ utilization and flat sequential growth. Despite a narrowed net loss, Geron remains unprofitable with no c...

4 months ago - Seeking Alpha

GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm.

4 months ago - Business Wire

Geron Corporation (GERN) Q1 2025 Earnings Call Transcript

Geron Corporation (NASDAQ:GERN) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Ron Maldiver - Investor Relations Dawn Bir - Interim President and Chief Executive Officer...

4 months ago - Seeking Alpha

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).

4 months ago - GlobeNewsWire

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported finan...

4 months ago - Business Wire

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In Geron To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Ne...

4 months ago - Accesswire

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,551,00...

4 months ago - Business Wire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Geron To Contact Him Directly To Discuss Their Options

5 months ago - GlobeNewsWire

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

GERN's Rytelo showed promising sales growth, with Q4'24 net product revenue increasing by 68% to $47.5M from Q3'24's $28.2M. Despite initial optimism, the market is concerned about a potential plateau...

5 months ago - Seeking Alpha

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its first quarter financial results and busin...

5 months ago - Business Wire

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 30...

Other symbols: CMRXCRVOCVSLLYNVOSEPN
5 months ago - Seeking Alpha

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

NEW YORK, NY / ACCESS Newswire / March 22, 2025 / Geron Corporation (NASDAQ:GERN) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties...

Other symbols: TBBK
5 months ago - Accesswire

Geron Corp: How Concerned Should We Be About Rytelo Sales?

Geron Corp's imetelstat, branded as Rytelo, launched in 2024 for lower-risk MDS, with promising expansion into myelofibrosis and other indications. Despite initial market enthusiasm, GERN's stock has ...

6 months ago - Seeking Alpha

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

LOS ANGELES , March 17, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Geron Corporation ("Geron" or "the Company") (NASDAQ: GERN) for violations of the fed...

6 months ago - PRNewsWire